Skip to main content
Top
Published in: Journal of Inflammation 1/2009

Open Access 01-12-2009 | Research

Modulation of expression and cellular distribution of p21 by macrophage migration inhibitory factor

Authors: Elliott Taranto, Jin R Xue, Eric F Morand, Michelle Leech

Published in: Journal of Inflammation | Issue 1/2009

Login to get access

Abstract

Background

The pleiotropic protein MIF, (macrophage migration inhibitory factor), has been demonstrated to modulate several key proteins governing cell cycle control and is considered to contribute to cell growth and differentiation. In this study we investigated the effect of MIF on the expression and cellular distribution of the CDK inhibitor p21.

Methods

The effect of endogenous MIF on p21 expression and distribution was examined by comparing murine dermal fibroblasts derived from wt and MIF -/- mice. The effect of MIF on cell growth and apoptotic rates was compared using 3H-Thymidine incorporation assays and annexin V/PI assays respectively. Total p21 protein levels were compared using flow cytometry and western blotting. p21 mRNA was assessed by RT-PCR. Intracellular p21 staining was performed to assess cellular distribution of total protein. To further confirm observations siRNA was used to knockdown MIF protein in wt cells. Cell cycle analysis was performed using PI incorporation assays.

Results

MIF-/- murine dermal fibroblasts exhibited reduced proliferative responses and were more susceptible to apoptosis. This was associated with reduced p21 expression and nuclear distribution. Treatment with recombinant MIF protein was demonstrated to reduce both basal and induced apoptosis and increase nuclear p21 expression. Reduced nuclear p21 expression was also observed in MIF siRNA treated wt cells.

Conclusion

The results demonstrate that in the absence of MIF p21 expression and nuclear distribution is reduced which is associated with a reduction in cell growth and increased apoptosis. MIF may therefore play a role in maintaining homeostatic control of p21.
Appendix
Available only for authorised users
Literature
1.
go back to reference Waldman T, Kinzler KW, Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995, 55: 5187-5190.PubMed Waldman T, Kinzler KW, Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995, 55: 5187-5190.PubMed
2.
go back to reference el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994, 54: 1169-1174.PubMed el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994, 54: 1169-1174.PubMed
3.
go back to reference Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ: The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. Embo J. 1999, 18: 1571-1583. 10.1093/emboj/18.6.1571.PubMedPubMedCentralCrossRef Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ: The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. Embo J. 1999, 18: 1571-1583. 10.1093/emboj/18.6.1571.PubMedPubMedCentralCrossRef
4.
go back to reference Alt JR, Gladden AB, Diehl JA: p21(Cip1) Promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem. 2002, 277: 8517-8523. 10.1074/jbc.M108867200.PubMedCrossRef Alt JR, Gladden AB, Diehl JA: p21(Cip1) Promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem. 2002, 277: 8517-8523. 10.1074/jbc.M108867200.PubMedCrossRef
5.
go back to reference Atanasoski S, Boller D, De Ventura L, Koegel H, Boentert M, Young P, Werner S, Suter U: Cell cycle inhibitors p21 and p16 are required for the regulation of Schwann cell proliferation. Glia. 2006, 53: 147-157. 10.1002/glia.20263.PubMedCrossRef Atanasoski S, Boller D, De Ventura L, Koegel H, Boentert M, Young P, Werner S, Suter U: Cell cycle inhibitors p21 and p16 are required for the regulation of Schwann cell proliferation. Glia. 2006, 53: 147-157. 10.1002/glia.20263.PubMedCrossRef
6.
go back to reference Scatizzi JC, Hutcheson J, Bickel E, Woods JM, Klosowska K, Moore TL, Haines GK, Perlman H: p21Cip1 is required for the development of monocytes and their response to serum transfer-induced arthritis. Am J Pathol. 2006, 168: 1531-1541. 10.2353/ajpath.2006.050555.PubMedPubMedCentralCrossRef Scatizzi JC, Hutcheson J, Bickel E, Woods JM, Klosowska K, Moore TL, Haines GK, Perlman H: p21Cip1 is required for the development of monocytes and their response to serum transfer-induced arthritis. Am J Pathol. 2006, 168: 1531-1541. 10.2353/ajpath.2006.050555.PubMedPubMedCentralCrossRef
7.
go back to reference Dong Y, Chi SL, Borowsky AD, Fan Y, Weiss RH: Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells. Cell Signal. 2004, 16: 263-269. 10.1016/S0898-6568(03)00136-0.PubMedCrossRef Dong Y, Chi SL, Borowsky AD, Fan Y, Weiss RH: Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells. Cell Signal. 2004, 16: 263-269. 10.1016/S0898-6568(03)00136-0.PubMedCrossRef
8.
go back to reference Dupont J, Karas M, LeRoith D: The cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells. J Biol Chem. 2003, 278: 37256-37264. 10.1074/jbc.M302355200.PubMedCrossRef Dupont J, Karas M, LeRoith D: The cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells. J Biol Chem. 2003, 278: 37256-37264. 10.1074/jbc.M302355200.PubMedCrossRef
9.
go back to reference Sun B, Nishihira J, Yoshiki T, Kondo M, Sato Y, Sasaki F, Todo S: Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res. 2005, 11: 1050-1058.PubMed Sun B, Nishihira J, Yoshiki T, Kondo M, Sato Y, Sasaki F, Todo S: Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res. 2005, 11: 1050-1058.PubMed
10.
go back to reference Leech M, Lacey D, Xue JR, Santos L, Hutchinson P, Wolvetang E, David JR, Bucala R, Morand EF: Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum. 2003, 48: 1881-1889. 10.1002/art.11165.PubMedCrossRef Leech M, Lacey D, Xue JR, Santos L, Hutchinson P, Wolvetang E, David JR, Bucala R, Morand EF: Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum. 2003, 48: 1881-1889. 10.1002/art.11165.PubMedCrossRef
11.
go back to reference Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999, 190: 1375-1382. 10.1084/jem.190.10.1375.PubMedPubMedCentralCrossRef Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999, 190: 1375-1382. 10.1084/jem.190.10.1375.PubMedPubMedCentralCrossRef
12.
go back to reference Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, Bucala R: Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA. 2002, 99: 345-350. 10.1073/pnas.012511599.PubMedPubMedCentralCrossRef Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, Bucala R: Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA. 2002, 99: 345-350. 10.1073/pnas.012511599.PubMedPubMedCentralCrossRef
13.
go back to reference Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR: Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med. 1999, 189: 341-346. 10.1084/jem.189.2.341.PubMedPubMedCentralCrossRef Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR: Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med. 1999, 189: 341-346. 10.1084/jem.189.2.341.PubMedPubMedCentralCrossRef
15.
go back to reference Morand EF, Leech M, Bernhagen J: MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov. 2006, 5: 399-410. 10.1038/nrd2029.PubMedCrossRef Morand EF, Leech M, Bernhagen J: MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov. 2006, 5: 399-410. 10.1038/nrd2029.PubMedCrossRef
16.
go back to reference Santos LL, Morand EF: The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis. Wien Med Wochenschr. 2006, 156: 11-18. 10.1007/s10354-005-0243-8.PubMedCrossRef Santos LL, Morand EF: The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis. Wien Med Wochenschr. 2006, 156: 11-18. 10.1007/s10354-005-0243-8.PubMedCrossRef
17.
go back to reference Mitchell RA: Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal. 2004, 16: 13-19. 10.1016/j.cellsig.2003.07.002.PubMedCrossRef Mitchell RA: Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal. 2004, 16: 13-19. 10.1016/j.cellsig.2003.07.002.PubMedCrossRef
18.
go back to reference Nishihira J, Ishibashi T, Fukushima T, Sun B, Sato Y, Todo S: Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. Ann N Y Acad Sci. 2003, 995: 171-182. 10.1111/j.1749-6632.2003.tb03220.x.PubMedCrossRef Nishihira J, Ishibashi T, Fukushima T, Sun B, Sato Y, Todo S: Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. Ann N Y Acad Sci. 2003, 995: 171-182. 10.1111/j.1749-6632.2003.tb03220.x.PubMedCrossRef
19.
go back to reference Mitchell RA, Bucala R: Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol. 2000, 10: 359-366. 10.1006/scbi.2000.0328.PubMedCrossRef Mitchell RA, Bucala R: Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol. 2000, 10: 359-366. 10.1006/scbi.2000.0328.PubMedCrossRef
20.
go back to reference Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE: Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res. 2003, 93: 321-329. 10.1161/01.RES.0000087641.56024.DA.PubMedCrossRef Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE: Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res. 2003, 93: 321-329. 10.1161/01.RES.0000087641.56024.DA.PubMedCrossRef
21.
go back to reference Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R: An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med. 1999, 5: 181-191.PubMedPubMedCentral Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R: An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med. 1999, 5: 181-191.PubMedPubMedCentral
22.
go back to reference Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR: Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther. 2007, 6: 1993-2002. 10.1158/1535-7163.MCT-07-0118.PubMedCrossRef Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR: Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther. 2007, 6: 1993-2002. 10.1158/1535-7163.MCT-07-0118.PubMedCrossRef
23.
go back to reference Onodera S, Suzuki K, Kaneda K, Fujinaga M, Nishihira J: Growth factor-induced expression of macrophage migration inhibitory factor in osteoblasts: relevance to the plasminogen activator system. Semin Thromb Hemost. 1999, 25: 563-568. 10.1055/s-2007-994966.PubMedCrossRef Onodera S, Suzuki K, Kaneda K, Fujinaga M, Nishihira J: Growth factor-induced expression of macrophage migration inhibitory factor in osteoblasts: relevance to the plasminogen activator system. Semin Thromb Hemost. 1999, 25: 563-568. 10.1055/s-2007-994966.PubMedCrossRef
24.
go back to reference Pelosi L, Giacinti C, Nardis C, Borsellino G, Rizzuto E, Nicoletti C, Wannenes F, Battistini L, Rosenthal N, Molinaro M, Musaro A: Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. Faseb J. 2007, 21: 1393-1402. 10.1096/fj.06-7690com.PubMedCrossRef Pelosi L, Giacinti C, Nardis C, Borsellino G, Rizzuto E, Nicoletti C, Wannenes F, Battistini L, Rosenthal N, Molinaro M, Musaro A: Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. Faseb J. 2007, 21: 1393-1402. 10.1096/fj.06-7690com.PubMedCrossRef
25.
go back to reference Lacey D, Sampey A, Mitchell R, Bucala R, Santos L, Leech M, Morand E: Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum. 2003, 48: 103-109. 10.1002/art.10733.PubMedCrossRef Lacey D, Sampey A, Mitchell R, Bucala R, Santos L, Leech M, Morand E: Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum. 2003, 48: 103-109. 10.1002/art.10733.PubMedCrossRef
26.
go back to reference Nguyen MT, Lue H, Kleemann R, Thiele M, Tolle G, Finkelmeier D, Wagner E, Braun A, Bernhagen J: The cytokine macrophage migration inhibitory factor reduces pro-oxidative stress-induced apoptosis. J Immunol. 2003, 170: 3337-3347.PubMedCrossRef Nguyen MT, Lue H, Kleemann R, Thiele M, Tolle G, Finkelmeier D, Wagner E, Braun A, Bernhagen J: The cytokine macrophage migration inhibitory factor reduces pro-oxidative stress-induced apoptosis. J Immunol. 2003, 170: 3337-3347.PubMedCrossRef
27.
go back to reference Nemajerova A, Mena P, Fingerle-Rowson G, Moll UM, Petrenko O: Impaired DNA damage checkpoint response in MIF-deficient mice. Embo J. 2007, 26: 987-997. 10.1038/sj.emboj.7601564.PubMedPubMedCentralCrossRef Nemajerova A, Mena P, Fingerle-Rowson G, Moll UM, Petrenko O: Impaired DNA damage checkpoint response in MIF-deficient mice. Embo J. 2007, 26: 987-997. 10.1038/sj.emboj.7601564.PubMedPubMedCentralCrossRef
28.
go back to reference Boulaire J, Fotedar A, Fotedar R: The functions of the cdk-cyclin kinase inhibitor p21WAF1. Pathol Biol (Paris). 2000, 48: 190-202. Boulaire J, Fotedar A, Fotedar R: The functions of the cdk-cyclin kinase inhibitor p21WAF1. Pathol Biol (Paris). 2000, 48: 190-202.
29.
go back to reference LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997, 11: 847-862. 10.1101/gad.11.7.847.PubMedCrossRef LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997, 11: 847-862. 10.1101/gad.11.7.847.PubMedCrossRef
30.
go back to reference Xu SQ, El-Deiry WS: p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun. 2000, 269: 179-190. 10.1006/bbrc.2000.2247.PubMedCrossRef Xu SQ, El-Deiry WS: p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun. 2000, 269: 179-190. 10.1006/bbrc.2000.2247.PubMedCrossRef
31.
go back to reference Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M: Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene. 1998, 17: 931-939. 10.1038/sj.onc.1202021.PubMedCrossRef Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M: Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene. 1998, 17: 931-939. 10.1038/sj.onc.1202021.PubMedCrossRef
32.
go back to reference Steinman RA, Johnson DE: p21WAF1 prevents down modulation of the apoptotic inhibitor protein c-IAP1 and inhibits leukemic apoptosis. Mol Med. 2000, 6: 736-749.PubMedPubMedCentral Steinman RA, Johnson DE: p21WAF1 prevents down modulation of the apoptotic inhibitor protein c-IAP1 and inhibits leukemic apoptosis. Mol Med. 2000, 6: 736-749.PubMedPubMedCentral
33.
go back to reference Suzuki A, Tsutomi Y, Miura M, Akahane K: Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene. 1999, 18: 1239-1244. 10.1038/sj.onc.1202409.PubMedCrossRef Suzuki A, Tsutomi Y, Miura M, Akahane K: Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene. 1999, 18: 1239-1244. 10.1038/sj.onc.1202409.PubMedCrossRef
34.
go back to reference Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S: Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999, 18: 1223-1234. 10.1093/emboj/18.5.1223.PubMedPubMedCentralCrossRef Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S: Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999, 18: 1223-1234. 10.1093/emboj/18.5.1223.PubMedPubMedCentralCrossRef
35.
go back to reference Hingorani R, Bi B, Dao T, Bae Y, Matsuzawa A, Crispe IN: CD95/Fas signaling in T lymphocytes induces the cell cycle control protein p21cip-1/WAF-1, which promotes apoptosis. J Immunol. 2000, 164: 4032-4036.PubMedCrossRef Hingorani R, Bi B, Dao T, Bae Y, Matsuzawa A, Crispe IN: CD95/Fas signaling in T lymphocytes induces the cell cycle control protein p21cip-1/WAF-1, which promotes apoptosis. J Immunol. 2000, 164: 4032-4036.PubMedCrossRef
36.
go back to reference Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M: Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res. 2001, 61: 6234-6238.PubMed Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M: Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res. 2001, 61: 6234-6238.PubMed
37.
go back to reference Franklin DS, Godfrey VL, O'Brien DA, Deng C, Xiong Y: Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol. 2000, 20: 6147-6158. 10.1128/MCB.20.16.6147-6158.2000.PubMedPubMedCentralCrossRef Franklin DS, Godfrey VL, O'Brien DA, Deng C, Xiong Y: Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol. 2000, 20: 6147-6158. 10.1128/MCB.20.16.6147-6158.2000.PubMedPubMedCentralCrossRef
38.
go back to reference Philipp J, Vo K, Gurley KE, Seidel K, Kemp CJ: Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis. Oncogene. 1999, 18: 4689-4698. 10.1038/sj.onc.1202840.PubMedCrossRef Philipp J, Vo K, Gurley KE, Seidel K, Kemp CJ: Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis. Oncogene. 1999, 18: 4689-4698. 10.1038/sj.onc.1202840.PubMedCrossRef
39.
go back to reference Adnane J, Jackson RJ, Nicosia SV, Cantor AB, Pledger WJ, Sebti SM: Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene. 2000, 19: 5338-5347. 10.1038/sj.onc.1203956.PubMedCrossRef Adnane J, Jackson RJ, Nicosia SV, Cantor AB, Pledger WJ, Sebti SM: Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene. 2000, 19: 5338-5347. 10.1038/sj.onc.1203956.PubMedCrossRef
40.
go back to reference Yasuda Y, Kasuya K, Nishihira J, Sasaki Y, Tsuchida A, Aoki T, Koyanagi Y: Induction of cell arrest by transfection of macrophage migration inhibitory factor antisense plasmid. Int J Mol Med. 2002, 10: 463-467.PubMed Yasuda Y, Kasuya K, Nishihira J, Sasaki Y, Tsuchida A, Aoki T, Koyanagi Y: Induction of cell arrest by transfection of macrophage migration inhibitory factor antisense plasmid. Int J Mol Med. 2002, 10: 463-467.PubMed
41.
go back to reference Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, Bucala R: Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA. 2002, 99: 345-350. 10.1073/pnas.012511599.PubMedPubMedCentralCrossRef Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, Bucala R: Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA. 2002, 99: 345-350. 10.1073/pnas.012511599.PubMedPubMedCentralCrossRef
42.
go back to reference Santos LL, Lacey D, Yang Y, Leech M, Morand EF: Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor. J Rheumatol. 2004, 31: 1038-1043.PubMed Santos LL, Lacey D, Yang Y, Leech M, Morand EF: Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor. J Rheumatol. 2004, 31: 1038-1043.PubMed
43.
go back to reference Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, Calandra T, Bucala R, Bernhagen J: Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal. 2006, 18: 688-703. 10.1016/j.cellsig.2005.06.013.PubMedCrossRef Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, Calandra T, Bucala R, Bernhagen J: Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal. 2006, 18: 688-703. 10.1016/j.cellsig.2005.06.013.PubMedCrossRef
44.
go back to reference Lee B, Moon SK: Ras/ERK signaling pathway mediates activation of the p21WAF1 gene promoter in vascular smooth muscle cells by platelet-derived growth factor. Arch Biochem Biophys. 2005, 443: 113-119. 10.1016/j.abb.2005.09.005.PubMedCrossRef Lee B, Moon SK: Ras/ERK signaling pathway mediates activation of the p21WAF1 gene promoter in vascular smooth muscle cells by platelet-derived growth factor. Arch Biochem Biophys. 2005, 443: 113-119. 10.1016/j.abb.2005.09.005.PubMedCrossRef
45.
go back to reference Kim YK, Bae GU, Kang JK, Park JW, Lee EK, Lee HY, Choi WS, Lee HW, Han JW: Cooperation of H2O2-mediated ERK activation with Smad pathway in TGF-beta1 induction of p21WAF1/Cip1. Cell Signal. 2006, 18: 236-243. 10.1016/j.cellsig.2005.04.008.PubMedCrossRef Kim YK, Bae GU, Kang JK, Park JW, Lee EK, Lee HY, Choi WS, Lee HW, Han JW: Cooperation of H2O2-mediated ERK activation with Smad pathway in TGF-beta1 induction of p21WAF1/Cip1. Cell Signal. 2006, 18: 236-243. 10.1016/j.cellsig.2005.04.008.PubMedCrossRef
46.
go back to reference Das D, Pintucci G, Stern A: MAPK-dependent expression of p21(WAF) and p27(kip1) in PMA-induced differentiation of HL60 cells. FEBS Lett. 2000, 472: 50-52. 10.1016/S0014-5793(00)01416-2.PubMedCrossRef Das D, Pintucci G, Stern A: MAPK-dependent expression of p21(WAF) and p27(kip1) in PMA-induced differentiation of HL60 cells. FEBS Lett. 2000, 472: 50-52. 10.1016/S0014-5793(00)01416-2.PubMedCrossRef
47.
go back to reference Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E: The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem. 2002, 277: 29792-29802. 10.1074/jbc.M201299200.PubMedCrossRef Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E: The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem. 2002, 277: 29792-29802. 10.1074/jbc.M201299200.PubMedCrossRef
48.
go back to reference Liao H, Bucala R, Mitchell RA: Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF). J Biol Chem. 2003, 278: 76-81. 10.1074/jbc.M208820200.PubMedCrossRef Liao H, Bucala R, Mitchell RA: Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF). J Biol Chem. 2003, 278: 76-81. 10.1074/jbc.M208820200.PubMedCrossRef
49.
go back to reference Swant JD, Rendon BE, Symons M, Mitchell RA: Rho GTPase-dependent signaling is required for macrophage migration inhibitory factor-mediated expression of cyclin D1. J Biol Chem. 2005, 280: 23066-23072. 10.1074/jbc.M500636200.PubMedPubMedCentralCrossRef Swant JD, Rendon BE, Symons M, Mitchell RA: Rho GTPase-dependent signaling is required for macrophage migration inhibitory factor-mediated expression of cyclin D1. J Biol Chem. 2005, 280: 23066-23072. 10.1074/jbc.M500636200.PubMedPubMedCentralCrossRef
50.
go back to reference Calandra T, Roger T: Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003, 3: 791-800. 10.1038/nri1200.PubMedCrossRef Calandra T, Roger T: Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003, 3: 791-800. 10.1038/nri1200.PubMedCrossRef
Metadata
Title
Modulation of expression and cellular distribution of p21 by macrophage migration inhibitory factor
Authors
Elliott Taranto
Jin R Xue
Eric F Morand
Michelle Leech
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2009
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-6-24

Other articles of this Issue 1/2009

Journal of Inflammation 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine